The UK and US have announced a landmark bilateral deal that will ensure no levies on British medicine exports being sold in the American market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has committed to increase expenditure on drugs through the National Health Service (NHS). This move guarantees that import taxes on these crucial products will stay at nothing for a timeframe of three years.
This agreement is in response to previous threats to hike tariffs on branded drug products, with increases floated as high as 100%.
"This agreement with the Britain strengthens the worldwide climate for innovative medicines and establishes much-needed equity to American-British drug exports," an announcement declared.
Commercial Importance
Medicines constitute one of the UK's most significant exports to the US, which is clearly the biggest destination for large companies like GSK and AstraZeneca.
Trade data show that in the one-year period prior to September, the UK sold pharmaceutical products worth over eleven billion pounds to the US. This value accounted for a significant portion of British export trade in that period.
"This agreement safeguards jobs, boosts capital expenditure and sets the stage for the UK to establish itself as a global hub for life sciences," a minister remarked.
Specific UK Commitments
The agreement includes several specific commitments from the British government:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it judges new medicines to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a goal to increase total health service expenditure on drugs from 0.3% of the national economy to 0.6% over the coming ten years.
- Refund Ceiling: The sum manufacturers must refund to the NHS to control costs will be limited at fifteen percent. Previously, rebates topped 20%.
Broader Context
This agreement comes amid a long-running dispute between the sector and the British authorities over medicine costs and NHS adoption.
These tensions were heightened by claims that American patients were charged several times more for the identical medicines than consumers in the UK and Europe.
In recent months, several significant drug company projects in the UK have been halted or abandoned, while substantial funding commitments have been directed toward US facilities.
The Science Minister stated that the NHS needed to increase expenditure on treatments, noting that its budget allocation on drugs had declined as a share of its resources over the past decade.
